Overview

Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

This is an open label long term follow up study, open to those subjects who were previously enrolled in"RAD001 Therapy of Angiomyolipomata in Patients with Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis", CCHMC IRB #2008-0812 and who meet the criteria for this long-term follow-up study. The hypothesis is that the drug will inhibit the growth of the angiomyolipomas and possibly even cause regression.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Children's Hospital Medical Center, Cincinnati

Collaborator:

Novartis

Treatments:

Everolimus
Sirolimus